Abstract Background and Purpose: While nephroureterectomy (NU) remains the gold-
standard treatment for upper-tract carcinoma in situ (UT-CIS), it may be unnecessarily …

The clinical benefits of bacillus Calmette–Guérin (BCG) therapy for the management of
upper urinary tract carcinoma in situ (CIS) remain unclear. We aimed to compare the efficacy …

Primary upper tract carcinoma in situ (UTcis) is a rare disease whose diagnosis and natural
history are poorly understood. Radical nephroureterectomy is the standard of care but in …

Objective To assess the long‐term efficacy of intrarenal bacillus Calmette‐Guérin (BCG)
therapy for the treatment of cytologically diagnosed upper tract carcinoma in situ (CIS) and …

There are few data on Bacillus Calmette-Guérin (BCG) therapy for upper urinary tract
carcinoma in situ (UUT CIS). We retrospectively evaluated the efficacy and tolerability of …

Background Radical nephroureterectomy (RNU) represents the gold standard treatment for
upper tract urothelial carcinoma (UTUC); however, attempts have been made to treat upper …

Background: We examined the long‐term outcome and compared the usefulness of
nephroureterectomy with that of bacillus Calmette‐Guérin (BCG) therapy for the …

Objectives: The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus
Calmette–Guérin (BCG) instillation as a treatment for transitional cell carcinoma in situ (CIS) …

Background and Purpose: We report our office-based technique and results of BCG and
interferon-α2B (BCG-IFN) for upper-tract transitional-cell carcinoma (TCC). Technique …

Context Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually
reported within the heterogeneous context of non–muscle-invasive bladder cancer (NMIBC) …